CLINICAL RESEARCH
Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients
Stefano Taddei, MD*,
Daniele Versari, MD,
Alessandro Cipriano, MD,
Lorenzo Ghiadoni, MD, PhD,
Fabio Galetta, MD,
Ferdinando Franzoni, MD,
Armando Magagna, MD,
Agostino Virdis, MD and
Antonio Salvetti, MD
Department of Internal Medicine, University of Pisa, Pisa, Italy
Manuscript received September 14, 2005;
revised manuscript received March 27, 2006,
accepted April 11, 2006.
* Reprint requests and correspondence: Dr. Stefano Taddei, Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy.
(Email: s.taddei{at}med.unipi.it).
OBJECTIVES: We assessed the role of cytochrome P450 2C9 (CYP 2C9)-derived endothelium-derived hyperpolarizing factor (EDHF) in the forearm microcirculation of essential hypertensive patients (EH) by utilizing sulfaphenazole (SUL), a selective CYP 2C9 inhibitor.
BACKGROUND: In EH patients, EDHF acts as a compensatory pathway when nitric oxide (NO) availability is reduced. Cytochrome P450 2C9 is a possible source of EDHF.
METHODS: In 36 healthy subjects (normotensive [NT]) and 32 hypertensive patients (HT), we studied forearm blood flow (strain-gauge plethysmography) changes induced by intraarterial acetylcholine (ACH) and bradykinin (BDK), repeated during NG-monomethyl-L-arginine (L-NMMA) (100 µg/100 ml/min) or SUL (0.03 mg/100 ml/min). In HT, the effect of SUL on ACH and BDK was repeated during vitamin C (8 mg/100 ml/min). Sodium nitroprusside (SNP) was utilized as control.
RESULTS: In NT, vasodilation to ACH and BDK was blunted by L-NMMA and not changed by SUL. In contrast, in HT responses to ACH and BDK, reduced compared with NT, were resistant to L-NMMA. In these patients, SUL blunted vasodilation to ACH and to a greater extent the response to BDK. When retested with vitamin C, SUL was no longer effective on both endothelial agonists. In 2 final groups of normotensive control subjects, vasodilation to ACH or BDK residual to cyclooxygenase and L-NMMA blockade was further inhibited by simultaneous SUL infusion. Response to SNP, similar between NT and HT, was unaffected by SUL.
CONCLUSIONS: Cytochrome P450 epoxygenase-derived EDHF acts as a partial compensatory mechanism to sustain endothelium-dependent vasodilation in HT, particularly the BDK-mediated response, when NO activity is impaired because of oxidative stress.
|
Abbreviations and Acronyms
| | ACH = acetylcholine | | BDK = bradykinin | | BP = blood pressure | | COX = cyclooxygenase | | CYP 2C = cytochrome P450 epoxygenase | | EDHF = endothelium-derived hyperpolarizing factor | | EET = epoxyeicosatrienoic acid | | FBF = forearm blood flow | | L-NMMA = NG-monomethyl-L-arginine | | NO = nitric oxide | | SNP = sodium nitroprusside |
|
This article has been cited by other articles:

|
 |

|
 |
 
Y. Chawengsub, K. M. Gauthier, K. Nithipatikom, B. D. Hammock, J. R. Falck, D. Narsimhaswamy, and W. B. Campbell
Identification of 13-Hydroxy-14,15-epoxyeicosatrienoic Acid as an Acid-stable Endothelium-derived Hyperpolarizing Factor in Rabbit Arteries
J. Biol. Chem.,
November 6, 2009;
284(45):
31280 - 31290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chawengsub, K. M. Gauthier, and W. B. Campbell
Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone
Am J Physiol Heart Circ Physiol,
August 1, 2009;
297(2):
H495 - H507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei
Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Circulation,
March 31, 2009;
119(12):
1625 - 1633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Donato, I. Eskurza, K. L. Jablonski, L. B. Gano, G. L. Pierce, and D. R. Seals
Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans
J Appl Physiol,
October 1, 2008;
105(4):
1359 - 1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway
Hypertension,
August 1, 2008;
52(2):
314 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Thum and J. Borlak
LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium
J. Biol. Chem.,
July 11, 2008;
283(28):
19456 - 19464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L Browne, D. R Meeking, S. Allard, L. J Munday, K. M Shaw, and M. H Cummings
Vasodilator prostanoids compensate for attenuated nitric oxide mediated vasodilation in type 1 diabetes
The British Journal of Diabetes & Vascular Disease,
November 1, 2007;
7(6):
288 - 294.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yada, H. Shimokawa, O. Hiramatsu, Y. Shinozaki, H. Mori, M. Goto, Y. Ogasawara, and F. Kajiya
Important Role of Endogenous Hydrogen Peroxide in Pacing-Induced Metabolic Coronary Vasodilation in Dogs In Vivo
J. Am. Coll. Cardiol.,
September 25, 2007;
50(13):
1272 - 1278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Fischer, U. Landmesser, S. Spiekermann, D. Hilfiker-Kleiner, M. Hospely, M. Muller, R. Busse, I. Fleming, and H. Drexler
Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure
Eur J Heart Fail,
August 1, 2007;
9(8):
770 - 775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Virdis, R. Colucci, M. Fornai, E. Duranti, C. Giannarelli, N. Bernardini, C. Segnani, C. Ippolito, L. Antonioli, C. Blandizzi, et al.
Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice
Hypertension,
March 1, 2007;
49(3):
679 - 686.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Campbell and J. R. Falck
Arachidonic Acid Metabolites as Endothelium-Derived Hyperpolarizing Factors
Hypertension,
March 1, 2007;
49(3):
590 - 596.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|